NCT03730961

An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function Given a Standard Dose of Loop Diuretic

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic.

Conditions

• Cardiac Failure
• Myocardial Failure
• Congestive Heart Failure
• Heart Decompensation

Interventions

Type	Name	Description
DRUG	BMS-986231	Intravenous administration
DRUG	Furosemide	Intravenous administration
DRUG	Placebo	Intravenous administration

Timeline

• Start date: 2019-01-17
• Primary completion: 2019-12-11
• Completion: 2020-01-09
• First posted: 2018-11-05
• Last updated: 2021-02-26
• Results posted: 2021-01-26

Locations

2 sites across 1 country: United Kingdom

Regulatory

• FDA-regulated drug study